Texas Permanent School Fund Corp Has $941,000 Holdings in Innoviva, Inc. (NASDAQ:INVA)

Texas Permanent School Fund Corp increased its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 16.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,381 shares of the biotechnology company’s stock after purchasing an additional 8,023 shares during the quarter. Texas Permanent School Fund Corp owned approximately 0.09% of Innoviva worth $941,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. EdgeRock Capital LLC bought a new stake in Innoviva during the 2nd quarter worth about $31,000. Bessemer Group Inc. increased its position in shares of Innoviva by 333.5% in the first quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 1,701 shares during the last quarter. Innealta Capital LLC bought a new stake in Innoviva during the second quarter worth about $33,000. GAMMA Investing LLC boosted its position in Innoviva by 124.0% during the first quarter. GAMMA Investing LLC now owns 2,262 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 1,252 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Innoviva during the first quarter valued at approximately $138,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on INVA shares. StockNews.com cut Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Innoviva in a research report on Tuesday, July 30th.

Innoviva Trading Down 1.6 %

Shares of NASDAQ:INVA opened at $19.36 on Friday. Innoviva, Inc. has a 52-week low of $12.22 and a 52-week high of $20.19. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70. The company has a market capitalization of $1.21 billion, a P/E ratio of 8.72 and a beta of 0.57. The company has a 50-day simple moving average of $18.71 and a 200 day simple moving average of $16.63.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter. Innoviva had a return on equity of 33.26% and a net margin of 44.00%. The company had revenue of $99.90 million during the quarter. Sell-side analysts forecast that Innoviva, Inc. will post 0.5 earnings per share for the current year.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.